BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 28181686)

  • 1. The Effect of a Histone Deacetylase Inhibitor (AR-42) on Canine Prostate Cancer Growth and Metastasis.
    Elshafae SM; Kohart NA; Altstadt LA; Dirksen WP; Rosol TJ
    Prostate; 2017 May; 77(7):776-793. PubMed ID: 28181686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastrin-releasing peptide receptor (GRPr) promotes EMT, growth, and invasion in canine prostate cancer.
    Elshafae SM; Hassan BB; Supsavhad W; Dirksen WP; Camiener RY; Ding H; Tweedle MF; Rosol TJ
    Prostate; 2016 Jun; 76(9):796-809. PubMed ID: 26939805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Canine prostatic cancer cell line (LuMa) with osteoblastic bone metastasis.
    Elshafae SM; Dirksen WP; Alasonyalilar-Demirer A; Breitbach J; Yuan S; Kantake N; Supsavhad W; Hassan BB; Attia Z; Alstadt LB; Rosol TJ
    Prostate; 2020 Jun; 80(9):698-714. PubMed ID: 32348616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of α(v)-integrins in stem/progenitor cells and supportive microenvironment impairs bone metastasis in human prostate cancer.
    van der Horst G; van den Hoogen C; Buijs JT; Cheung H; Bloys H; Pelger RC; Lorenzon G; Heckmann B; Feyen J; Pujuguet P; Blanque R; Clément-Lacroix P; van der Pluijm G
    Neoplasia; 2011 Jun; 13(6):516-25. PubMed ID: 21677875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergy of Histone-Deacetylase Inhibitor AR-42 with Cisplatin in Bladder Cancer.
    Li DR; Zhang H; Peek E; Wang S; Du L; Li G; Chin AI
    J Urol; 2015 Aug; 194(2):547-55. PubMed ID: 25748177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AR-42 induces apoptosis in human hepatocellular carcinoma cells via HDAC5 inhibition.
    Zhang M; Pan Y; Dorfman RG; Chen Z; Liu F; Zhou Q; Huang S; Zhang J; Yang D; Liu J
    Oncotarget; 2016 Apr; 7(16):22285-94. PubMed ID: 26993777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lycorine is a novel inhibitor of the growth and metastasis of hormone-refractory prostate cancer.
    Hu M; Peng S; He Y; Qin M; Cong X; Xing Y; Liu M; Yi Z
    Oncotarget; 2015 Jun; 6(17):15348-61. PubMed ID: 25915156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
    Shabbeer S; Kortenhorst MS; Kachhap S; Galloway N; Rodriguez R; Carducci MA
    Prostate; 2007 Jul; 67(10):1099-110. PubMed ID: 17477369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valproic acid (VPA) inhibits the epithelial-mesenchymal transition in prostate carcinoma via the dual suppression of SMAD4.
    Lan X; Lu G; Yuan C; Mao S; Jiang W; Chen Y; Jin X; Xia Q
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):177-85. PubMed ID: 26206483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer.
    Jacob S; Nayak S; Fernandes G; Barai RS; Menon S; Chaudhari UK; Kholkute SD; Sachdeva G
    Endocr Relat Cancer; 2014 Jun; 21(3):473-86. PubMed ID: 24812058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel histone deacetylase inhibitor AR-42 exhibits antitumor activity in pancreatic cancer cells by affecting multiple biochemical pathways.
    Chen YJ; Wang WH; Wu WY; Hsu CC; Wei LR; Wang SF; Hsu YW; Liaw CC; Tsai WC
    PLoS One; 2017; 12(8):e0183368. PubMed ID: 28829799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory action of pristimerin on hypoxia‑mediated metastasis involves stem cell characteristics and EMT in PC-3 prostate cancer cells.
    Zuo J; Guo Y; Peng X; Tang Y; Zhang X; He P; Li S; Wa Q; Li J; Huang S; Xu D
    Oncol Rep; 2015 Mar; 33(3):1388-94. PubMed ID: 25571882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells.
    Shigemura K; Arbiser JL; Sun SY; Zayzafoon M; Johnstone PA; Fujisawa M; Gotoh A; Weksler B; Zhau HE; Chung LW
    Cancer; 2007 Apr; 109(7):1279-89. PubMed ID: 17326044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice.
    Angelucci A; Gravina GL; Rucci N; Millimaggi D; Festuccia C; Muzi P; Teti A; Vicentini C; Bologna M
    Endocr Relat Cancer; 2006 Mar; 13(1):197-210. PubMed ID: 16601288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting cathepsin K diminishes prostate cancer establishment and growth in murine bone.
    Liang W; Wang F; Chen Q; Dai J; Escara-Wilke J; Keller ET; Zimmermann J; Hong N; Lu Y; Zhang J
    J Cancer Res Clin Oncol; 2019 Aug; 145(8):1999-2012. PubMed ID: 31172267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer.
    Canesin G; Evans-Axelsson S; Hellsten R; Sterner O; Krzyzanowska A; Andersson T; Bjartell A
    Eur Urol; 2016 Mar; 69(3):400-4. PubMed ID: 26144873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formation of AR-SMRT binding in prostate cancer cells treated with natural histone deacetylase inhibitor.
    Trtková K; Pašková L; Matiješčuková N; Kolář Z
    Cancer Biomark; 2010; 7(2):79-90. PubMed ID: 21178266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Dickkopf-1 (DKK-1) on Prostate Cancer Growth and Bone Metastasis.
    Yuan S; Hoggard NK; Kantake N; Hildreth BE; Rosol TJ
    Cells; 2023 Nov; 12(23):. PubMed ID: 38067123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo.
    Wang M; Liu X; Guo J; Weng X; Jiang G; Wang Z; He L
    Biochem Biophys Res Commun; 2015 Nov; 467(2):310-5. PubMed ID: 26435505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex.
    von Burstin J; Eser S; Paul MC; Seidler B; Brandl M; Messer M; von Werder A; Schmidt A; Mages J; Pagel P; Schnieke A; Schmid RM; Schneider G; Saur D
    Gastroenterology; 2009 Jul; 137(1):361-71, 371.e1-5. PubMed ID: 19362090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.